ABSTRACT
OBJECTIVE: To compare the vestibular function and clinical aspects (vestibular and migraine symptoms) of patients divided into three groups-migraine without aura, migraine with aura, and chronic migraine-and a control group by using electronystagmography and a design questionnaire. STUDY DESIGN: Case-control study. SETTING: Tertiary referral center. PATIENTS: Women aged between 18 and 55 years diagnosed with migraine with aura, migraine without aura, or chronic migraine according to the International Classification of Headache Disorders ICHD-third edition; diagnosis was made by a headache specialist. The control group consisted of patients' family members and hospital employees without a personal history of headache. MAIN OUTCOME MEASURES: Application of a questionnaire regarding vestibular symptoms and their relation to migraine aspects. Assessment of the vestibular function by electronystagmography. RESULTS: This study evaluated 120 female patients. Dizziness was the most prevalent vestibular symptom in all the migraine groups, with higher prevalence in the episodic migraine with aura and chronic migraine groups. Phonophobia and photophobia during vestibular symptoms also had greater prevalence in the latter groups. Electronystagmography tests did not reveal differences among the groups, but clinical stratification showed that tests with mixed etiology abnormalities were more prevalent in the episodic migraine with aura and chronic migraine groups. CONCLUSION: The prevalence of vestibular symptoms in the migraine groups and the etiology of vestibular impairment highlight that migraine affects the vestibular system. Our findings suggest that symptom progression and vestibular impact are related to migraine chronicity and presence of aura.
Subject(s)
Migraine with Aura , Migraine without Aura , Humans , Female , Adolescent , Young Adult , Adult , Middle Aged , Dizziness/etiology , Dizziness/diagnosis , Case-Control Studies , Vertigo , HeadacheABSTRACT
OBJETIVO: avaliar a satisfação do usuário de AAS (Aparelho de Amplificação Sonora) por meio da aplicação do questionário de autoavaliação IOI-HA (International Outcome Inventory For Hearing Aids) e correlacioná-lo às características dos indivíduos, da perda auditiva e do processo de adaptação do AAS. MÉTODO: foram avaliados 98 indivíduos, de ambos os gêneros, com perda auditiva neurossensorial, de um serviço público e usuários sistemáticos de AAS há, pelo menos, três meses. O questionário IOI-HA foi aplicado, como roteiro de entrevista estruturada, aos indivíduos. Correlacionaram-se as variáveis estudadas com o nível de satisfação do usuário, analisado pelo IOI-HA, por meio do fator 1 (que reflete a interação do indivíduo com seu AAS), o fator 2 (relacionado à interação do indivíduo com outras pessoas no seu ambiente) e a pontuação total de cada indivíduo. RESULTADOS: não houve correlação significante entre as variáveis estudadas e o nível de satisfação do usuário. Entretanto, é importante ressaltar que as médias obtidas nas análises, por item, foram positivas e, consequentemente, as análises da soma total do IOI-HA, fator 1 e fator 2, também foram positivas e se aproximaram dos escores máximos para cada fator. CONCLUSÃO: o presente estudo constatou que, no grupo estudado, os usuários de AAS estavam satisfeitos com a adaptação de seus aparelhos e não foram observadas correlações entre as variáveis estudadas e o grau de satisfação do usuário de AAS, por meio do questionário IOI-HA.
PURPOSE: assess satisfaction with hearing aids (HA) by applying the self-assessment questionnaire IOI-HA (International Outcome Inventory for Hearing Aids) and to correlate the characteristics of hearing loss and HA fitting process. METHOD: 98 patients from a healthy public service were assessed, of both genders, with sensorineural hearing loss, and using the HA in a systematic way for at least 3 months. The IOI-HA questionnaire was used as a guide directed structured interview with the patient. Correlated these variables with the level of user satisfaction analyzed by IOI-HA by a factor (which reflects the interaction of the patient with his HA), the second factor (related to the patient's experience with other people in their environment), and the total score for each patient. RESULTS: there was no significant correlation between these variables and user satisfaction. However, it is important to note that the averages obtained were positive and therefore the analyzes of the total sum of the IOI-HA, Factors 1 and 2, were also positive and approached the maximum score for each factor. CONCLUSION: this study found that in the studied group of HA users were satisfied with the adaptation of their HA and there were no correlations between variables and the degree of satisfaction with HA through the IOI-HA questionnaire.
ABSTRACT
Há comprovação de que o fenômeno de resistência ocorre quando a dose não lesiva da amicacina protege as células ciliadas contra a ototoxicidade da própria amicacina. OBJETIVO: O objetivo deste trabalho é verificar se o fenômeno de resistência é temporalmente persistente. MÉTODO: Estudo experimental com 14 cobaias albinas (Cavia porcellus) divididas em três grupos. Avaliação da função auditiva por emissões otoacústicas por produto de distorção (EOAPD): na pré-exposição à amicacina, no 15º dia de aplicação da dose não lesiva, no final da aplicação da dose lesiva e antes da decapitação. RESULTADOS: O Grupo A (controle) apresentou função auditiva e padrão histológico normais. No Grupo B (amicacina 20mg/kg/dia intramuscular por 30 dias e dose lesiva (400 mg/kg/dia) por 12 dias) e no Grupo C (mesmo esquema do grupo B, porém mantidos por 60 dias e sacrificados), as OEA-PD confirmaram função auditiva normal no período pré-exposição e manutenção do padrão após dose não lesiva, porém, houve perda importante da função auditiva após término do período de aplicação da dose lesiva. CONCLUSÃO: Não houve manutenção do fenômeno da autodefesa estendida por um período de 30 a 60 dias após a aplicação de doses lesivas de amicacina.
There is evidence that a "resistance phenomenon" occurs when a none-damaging dose of amikacin protects the hair cells from ototoxicity. Our goal is to prove that this resistance is persistent. METHOD: Experimental study - 14 albino guinea pigs (Cavia porcellus) divided into three groups. The auditory function was assessed by distortion product otoacoustic emissions (DPOAE): before exposure to amikacin, on the 15th day after the non-damaging dose was injected, at the end of the damage dose injection and prior to decapitation. RESULTS: Group A (control) presented normal hearing and histological pattern. Group B (amikacin 20mg/kg/day (IM) for 30 days and affecting dose (400 mg / kg / day) for 12 days and Group C (same protocol of Group B, but kept for 60 days and slaughtered), the DPOAE confirmed normal auditory function in the pre-exposure and maintenance of the standard-dose; however, significant loss of auditory function after the end of the damaging dose injection. CONCLUSION: The protection phenomenon did not extended for a period of 30 to 60 days after the application of damaging doses of amykacin.
Subject(s)
Animals , Guinea Pigs , Amikacin/toxicity , Anti-Bacterial Agents/toxicity , Hair Cells, Auditory, Outer/drug effects , Hearing Loss/chemically induced , Otoacoustic Emissions, Spontaneous/drug effects , Amikacin/administration & dosage , Anti-Bacterial Agents/administration & dosage , Dose-Response Relationship, Drug , Hair Cells, Auditory, Outer/ultrastructure , Microscopy, Electron, Scanning , Time FactorsABSTRACT
UNLABELLED: There is evidence that a "resistance phenomenon" occurs when a none-damaging dose of amikacin protects the hair cells from ototoxicity. Our goal is to prove that this resistance is persistent. METHOD: Experimental study - 14 albino guinea pigs (Cavia porcellus) divided into three groups. The auditory function was assessed by distortion product otoacoustic emissions (DPOAE): before exposure to amikacin, on the 15th day after the non-damaging dose was injected, at the end of the damage dose injection and prior to decapitation. RESULTS: Group A (control) presented normal hearing and histological pattern. Group B (amikacin 20mg/kg/day (IM) for 30 days and affecting dose (400 mg / kg / day) for 12 days and Group C (same protocol of Group B, but kept for 60 days and slaughtered), the DPOAE confirmed normal auditory function in the pre-exposure and maintenance of the standard-dose; however, significant loss of auditory function after the end of the damaging dose injection. CONCLUSION: The protection phenomenon did not extended for a period of 30 to 60 days after the application of damaging doses of amykacin.
